Regeneron Pharmaceuticals, Inc. (REGN) Posts Q3 adj.-EPS of $2.40

November 5, 2013 6:31 AM EST
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) reported Q3 EPS of $2.40, $1.48 better than the analyst estimate of $0.92. Revenue for the quarter came in at $597 million versus the consensus estimate of $501.93 million.

For earnings history and earnings-related data on Regeneron Pharmaceuticals, Inc. (REGN) click here.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Earnings

Related Entities

Earnings